Patrick J. Mcenany - Nov 13, 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director, Chairman of Board of Directors
Signature
/s/ Patrick J. McEnany
Stock symbol
CPRX
Transactions as of
Nov 13, 2024
Transactions value $
-$2,611,272
Form type
4
Date filed
11/15/2024, 05:00 PM
Previous filing
Nov 13, 2024
Next filing
Nov 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $327K +92.5K +2.07% $3.54 4.57M Nov 13, 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$2.13M -92.5K -2.02% $22.98 4.48M Nov 13, 2024 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $158K +44.7K +1% $3.54 4.52M Nov 14, 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$971K -44.7K -0.99% $21.75 4.48M Nov 14, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -92.5K -4.4% $0.00 2.01M Nov 13, 2024 Common Stock 92.5K $3.54 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -44.7K -2.22% $0.00 1.96M Nov 14, 2024 Common Stock 44.7K $3.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $22.82 to $23.13 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.52 to $22.20 per share.
F4 Options vested in three equal tranches on May 29, 2019, 2020 and 2021.